Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 2
2008 1
2009 4
2010 2
2011 6
2012 2
2013 12
2014 15
2015 8
2016 8
2017 10
2018 6
2019 5
2020 1
2021 7
2022 4
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Results by year

Filters applied: . Clear all
Page 1
Alleviating cancer drug toxicity by inhibiting a bacterial enzyme.
Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, Venkatesh M, Jobin C, Yeh LA, Mani S, Redinbo MR. Wallace BD, et al. Among authors: koo js. Science. 2010 Nov 5;330(6005):831-5. doi: 10.1126/science.1191175. Science. 2010. PMID: 21051639 Free PMC article.
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panés J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass A; QUASAR Study Group. Peyrin-Biroulet L, et al. Gastroenterology. 2023 Dec;165(6):1443-1457. doi: 10.1053/j.gastro.2023.08.038. Epub 2023 Sep 1. Gastroenterology. 2023. PMID: 37659673 Free article. Clinical Trial.
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
Danese S, Colombel JF, Lukas M, Gisbert JP, D'Haens G, Hayee B, Panaccione R, Kim HS, Reinisch W, Tyrrell H, Oh YS, Tole S, Chai A, Chamberlain-James K, Tang MT, Schreiber S; GARDENIA Study Group. Danese S, et al. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):118-127. doi: 10.1016/S2468-1253(21)00294-6. Epub 2021 Nov 17. Lancet Gastroenterol Hepatol. 2022. PMID: 34798038 Free article. Clinical Trial.
Rifampin-induced Pseudomembranous Colitis with Rectosigmoid Sparing.
Yim SY, Koo JS, Kim YJ, Park SJ, Kim JN, Jung SW, Yim HJ, Lee SW, Choi JH, Kim CD. Yim SY, et al. Among authors: koo js. Clin Endosc. 2011 Dec;44(2):137-9. doi: 10.5946/ce.2011.44.2.137. Epub 2011 Dec 31. Clin Endosc. 2011. PMID: 22741126 Free PMC article.
Predictive Factors of Atelectasis Following Endoscopic Resection.
Choe JW, Jung SW, Song JK, Shim E, Choo JY, Kim SY, Hyun JJ, Koo JS, Yim HJ, Lee SW. Choe JW, et al. Among authors: koo js. Dig Dis Sci. 2016 Jan;61(1):181-8. doi: 10.1007/s10620-015-3844-0. Epub 2015 Aug 20. Dig Dis Sci. 2016. PMID: 26289260
Comparison of the Pharmacokinetics of CT-P13 Between Crohn's Disease and Ulcerative Colitis.
Kim ES, Kim SK, Park DI, Kim HJ, Lee YJ, Koo JS, Kim ES, Yoon H, Lee JH, Kim JW, Shin SJ, Kim HW, Kim HS, Park YS, Kim YS, Kim TO, Lee J, Choi CH, Han DS, Chun J, Kim HS; IBD Research Group in the Korean Association for the Study of Intestinal Diseases. Kim ES, et al. Among authors: koo js. J Clin Gastroenterol. 2023 Jul 1;57(6):601-609. doi: 10.1097/MCG.0000000000001715. J Clin Gastroenterol. 2023. PMID: 35470308
94 results